Already reeling from Merck & Co.'s decision earlier this week to scrap a planned R&D facility in London, the UK's pharmaceutical sector has been dealt another blow with a damning assessment of the sector's health from the Association of the British Pharmaceutical Industry (ABPI). In a newly-published report assessing the competitiveness of various countries' drug industries, the ABPI said that the UK has been underperforming on a number of measures starting in 2017. And while the analysis sugges

NEWTOWN, Pa., Sept. 11, 2025 /PRNewswire/ -- Edelson Lechtzin LLP is investigating potential violations of the federal securities laws involving Lantheus Holdings, Inc. ("Lantheus") (NASDAQ: LNTH), resulting from allegations of providing potentially misleading business information to the investing public. If you have information that could assist in the Lantheus investigation or if you are a Lantheus investor who suffered a loss and would like to learn more, you can provide your information HE

The Federal Trade Commission announced yesterday that it sent letters to many large health care employers and staffing firms, urging them to review their employment agreements — including any noncompete agreements — to ensure they are in compliance. The commission's announcement follows one from Sept. 5 , when it moved to vacate a 2024 noncompete final rule, voting 3-1 to dismiss appeals initiated by the previous administration attempting to uphold it. On Sept. 4 , the FTC issued a request for i

The AHA today expressed support for the Resident Physician Shortage Reduction Act ( H.R. 4731 / S. 2439 ) to House and Senate sponsors of the bills. The bipartisan legislation would add 14,000 Medicare-funded residency positions over seven years to help alleviate ongoing physician shortages. The bills would direct a significant portion of the new slots to rural hospitals, hospitals training above their existing resident caps, hospitals in states with new medical schools or campuses, and hospital

New Delhi: Days after the GST Council slashed the indirect tax on medicines from 12 per cent to 5 per cent under the new two-tier regime, India’s apex drug regulator, CDSCO has asked state regulators to “expedite” no-objection clearance for restickering drug labels to reflect the revised retail rates. Issuing a directive to state drug controllers, the Drugs Controller General of India (DCGI), Dr Rajeev Singh Raghuvashi has conveyed, “to expedite the process of issuance of no objection for altera

New Delhi: The new rule by India's drug regulatory authority, which restricts export of pharmaceutical products labelled as "For sale in India only" is causing huge losses to the exporters and depriving people of affordable medicines, people in the know told ET. The Federation of Pharmaceutical and Allied Products Merchant Exporters (FPME) has raised their concerns with the health ministry and commerce ministry urging to repeal the rule which was introduced last year by the drug regulatory autho

Bengaluru: AbbVie shares rose 4 per cent to a record high on Thursday after the U.S. drugmaker said it expected no generic competition for its blockbuster immunology drug Rinvoq until 2037, a four-year extension, according to some analysts. Rinvoq, used for the treatment of rheumatoid arthritis and other autoimmune diseases, is AbbVie's second best-selling drug behind Skyrizi. The company has been doubling down on the immunology treatments to counter the drop in sales of arthritis treatment Humi

London: A federal appeals court on Thursday rejected Eli Lilly 's appeal of an $183.7 million judgment won by a whistleblowing lawyer and pharmacist who accused the drugmaker of defrauding Medicaid. The 7th U.S. Circuit Court of Appeals in Chicago said a federal jury reasonably found that Lilly knowingly concealed having retroactively increased prices on some drugs, and then failing to rebate Medicaid on the higher prices. Circuit Judge Joshua Kolar said jurors heard "ample evidence" suggesting

Results of the successful phase 3 TETON-2 study of inhaled treprostinil in idiopathic pulmonary fibrosis will be presented in an oral presentation SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that recent research across its commercial and development portfolio will be presented at the European Respiratory Society (ERS) Congress in Amsterdam, Netherlands on September 27 - October

DURHAM, N.C.--(BUSINESS WIRE)--Sep. 12, 2025-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that the Company presented clinical data from the Phase 1 ELIMINATE-B trial of PBGENE-HBV in patients with chronic Hepatitis B. The data was presented at the International Coalition to Eliminate HBV (ICE-HBV) “HBV Cure Symposium” Meeti